Investors

Vididencel to be developed as a post-remission therapy across AML risk categories and in CML

Expanding the vididencel opportunity

The board of directors of Mendus AB (publ) ("Mendus") has decided, based on the authorization from the Annual General Meeting on 6 May 2025, to transfer own shares on Nasdaq Stockholm

Mendus AB (“Mendus” publ; IMMU.ST), will publish its interim report for the second quarter 2025 on August 21 at 08.00 CEST. The company will host a live presentation and business update on the same day at 14.00 CEST. The presentation will be held in English and includes a Q&A session

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence in life-threatening cancers, today announces that the United States Patent and Trademark Office (USPTO) has granted a patent in the US covering the use of Mendus’ lead product vididencel in ovarian cancer. The patent further validates vididencel’s potential in ovarian cancer, following positive clinical data presented at the ASCO 2025 conference

As previously announced, Mendus AB (publ) (“Mendus”) has, pursuant to the authorizations granted by the shareholders at the Annual General Meeting on May 6, 2025, issued a total of 1,725,000 Class C shares in order to facilitate payment of remuneration to board members and bonuses to employees in shares as well as to preserve liquidity. All Class C shares have been converted into ordinary shares

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence in life-threatening cancers, today announces a summary of the data presented at the 30th European Hematology Association Congress (EHA), held from June 12 to June 15, 2025, in Milan Italy. The clinical data presented based on the European ADVANCE II Phase 2 clinical trial confirms that vididencel acts as a mutation-agnostic immunotherapy in acute myeloid leukemia (AML), supporting a broad positioning as post-clinical remission therapy, independent of specific mutations in this indication

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence in life-threatening cancers, today announces a summary of the data presented at the 61st Annual American Society of Clinical Oncology conference (ASCO 2025) held from May 30 to June 3, 2025, in Chicago, Illinois, from the ongoing ALISON trial with Mendus’ lead product vididencel in ovarian cancer. The data demonstrate that stable disease is associated with the successful induction of tumor-directed immune responses following vididencel treatment in this indication

As authorized by shareholders at the Annual General Meeting on May 6, 2025, Mendus AB (publ) ("Mendus") has decided to issue and subsequently immediately repurchase Class C shares in order to facilitate payment of remuneration to board members and bonuses to employees in shares

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces a summary of the data presented at the 2025 Cancer Immunotherapy Conference (CIMT), held May 12-14 in Mainz, Germany. The data demonstrate increased T cell diversity following treatment with Mendus’ lead product vididencel in acute myeloid leukemia (AML) and support the use of Mendus’ DCOne platform to expand tumor-infiltrating lymphocytes for the treatment of solid tumors